Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastrointestinal Neoplasms 2Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 288Capecitabine 218Fluorouracil 212Irinotecan 145Leucovorin 139Gemcitabine 125S 1 (combination) 110apatinib 109Cisplatin 102Drug Therapy 98Radiotherapy 97Paclitaxel 97Bevacizumab 97camrelizumab 89sintilimab 79Cetuximab 75lenvatinib 62Neoadjuvant Therapy 61tislelizumab 55Surgical Procedures, Operative 54toripalimab 53Sorafenib 53Folfox protocol 53Docetaxel 52130-nm albumin-bound paclitaxel 47Laparoscopy 41HMPL-013 40XELOX 39Radiosurgery 36Albumin-Bound Paclitaxel 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × CGX1321 × Gastrointestinal × Clear all
NCT02675946 2022-01-26

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Curegenix Inc.

Phase 1 Unknown
72 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT03507998 2020-07-24

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Curegenix Inc.

Phase 1 Unknown
39 enrolled
Gastrointestinal

Bile Duct Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡